Join the club for FREE to access the whole archive and other member benefits.

Michael Kope

Co-Chief Executive Officer and Co-founder Underdog Pharmaceuticals

Established SENS Research Foundation in 2009 with Aubrey de Grey, and was its founding CEO, serving until 2019.

Received his J.D. from the University of Michigan in 1990. He has served as the University of Michigan’s Intellectual Property Counsel; Director of Corporate Development for Aviron/MedImmune, Inc.; and as CEO and officer of a number of biotechnology startups.

Visit website: https://underdogpharma.com/team/#kope

 michael-kope-39331a78

See also: Company Cyclarity Therapeutics - Company developing simple and direct interventions targeting toxic forms of cholesterol for age-related diseases

Details last updated 29-Oct-2020

Mentioned in this Resource

SENS Research Foundation

Non-profit organization focused on transforming the way the world researches and treats age-related diseases

Michael Kope is also referenced in the following:

Cyclarity Therapeutics

Company developing simple and direct interventions targeting toxic forms of cholesterol for age-related diseases

Rejuvenation Startup Summit 2024

10-May-2024 to 11-May-2024

The leading networking event for rejuvenation startups, longevity investors and translational researchers by Forever Healthy Foundation

SENS Annual Report 2020

Quick summary of SENS’ latest research projects and other activities

Michael Kope News

Reason reports back from October's Rejuvenation Startup Summit

Reason reports back from October's Rejuvenation Startup Summit

Fight Aging! - 19-Oct-2022

Some really exciting developments with quite a few in clinical trials

Racing for the lead... Underdog becomes Cyclarity Therapeutics

Racing for the lead... Underdog becomes Cyclarity Therapeutics

Longevity Technology - 20-Jun-2022

Also announces move to Buck Institute for Research on Aging

Underdog pharmaceuticals secures $10m funding from Kizoo ventures

Underdog pharmaceuticals secures $10m funding from Kizoo ventures

Longevity Technology - 23-Sep-2021

Funds to bring affordable and effective age-related therapies to the public